From DCAT Value Chain Insights (VCI)
The Generic Pharmaceutical Association (GPhA) has launched the Biosimilars Council, a division of GPhA. "The Biosimilars Council will comprise manufacturers and stakeholders working to ensure a positive regulatory, reimbursement, political, and policy environment that supports patient access to these more affordable new medicines," said the GPhA in a statement. "The Biosimilars Council also is the industry’s first educational resource for the general public and patient groups seeking information about the safety and effectiveness of biosimilars."
Among the first offerings of the Biosimilars Council is a new educational handbook, The Next Frontier for Improved Access to Medicines: Biosimilars and Interchangeable Biologic Products. This publication explains the science behind biosimilar medicines, access to these medicines, the legal and regulatory framework for biosimilars, and the manufacturing and development process of biosimilars.
As per recently adopted changes to the GPhA bylaws, a Biosimilar Board, elected by members of the Biosimilars Council, will develop the association’s biosimilar activities.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription